Company news

Alumis Inc. news in 2025

Alumis Inc.'s news releases, calls and decks from 2025, newest first.

View company

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

November 13, 2025

Alumis to Participate in Upcoming November Investor Conferences

November 4, 2025

Alumis to Participate in Upcoming September Investor Conferences

August 29, 2025

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

July 24, 2025

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

July 14, 2025

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025

Alumis Completes Merger with ACELYRIN

May 21, 2025

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

May 12, 2025

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

May 1, 2025

Alumis and ACELYRIN Announce Amended Merger Agreement

April 21, 2025

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

April 4, 2025

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

March 25, 2025

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

March 19, 2025

Alumis to Present at Leerink's 2025 Global Healthcare Conference

March 10, 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

March 8, 2025

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

March 4, 2025

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

March 4, 2025

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

February 28, 2025

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

February 27, 2025

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

February 19, 2025

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 9, 2025

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

February 5, 2025

Alumis Strengthens Leadership Team with Key Appointments

January 27, 2025

Decks in 2025